Addressing Challenges With New Therapies in Prostate Cancer

William K. Oh, MD, discusses phase III studies in the prostate cancer setting which led to the use of these new treatments, such as androgen receptor targeted therapies with chemotherapy in earlier disease settings.

William K. Oh, MD, chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System, discusses phase III studies in the prostate cancer setting which led to the use of these new treatments, such as androgen receptor targeted therapies with chemotherapy in earlier disease settings.

According to Oh, many of the new therapies which started in castration-resistant prostate cancer, are now being used earlier, in settings including nonmetastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. This puts physicians in a position where there is uncertainty of how to treat when their patients relapse after treatment since these drugs are not curative, says Oh.

Because there are so many choices in therapies, the question arises of how to sequence treatments. Oh exemplifies the metastatic hormone-sensitive patient population where physicians can use chemotherapy with either abiraterone acetate (Zytiga), enzalutamide (Xtandi), or apalutamide (Erleada).

Optimizing the current treatment options is necessary to provide patients with the best outcomes, says Oh. This remains a major challenge in the treatment landscape of prostate cancer.

<< View more resources and information regarding prostate cancer